OncomiR or antioncomiR: Role of miRNAs in Acute Myeloid Leukemia

被引:20
|
作者
He, Chengcheng [1 ,2 ]
Luo, Bo [2 ]
Jiang, Nan [2 ]
Liang, Yu [2 ]
He, Yancheng [2 ]
Zeng, Jingyuan [2 ]
Liu, Jiajia [2 ]
Zheng, Xiaoli [2 ]
机构
[1] Peoples Hosp Zhongjiang, Deyang, Sichuan, Peoples R China
[2] Southwest Med Univ, Coll Preclin Med, Luzhou 646000, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
OncomiR; antioncomiR; Acute Myeloid Leukemia; microRNA; ACUTE PROMYELOCYTIC LEUKEMIA; INHIBITS CELL-PROLIFERATION; TUMOR-SUPPRESSOR; UP-REGULATION; ENHANCES CHEMOSENSITIVITY; THERAPEUTIC APPLICATION; DRUG-SENSITIVITY; ARSENIC TRIOXIDE; TARGETING HMGB1; SELF-RENEWAL;
D O I
10.1080/10428194.2018.1480769
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute Myeloid Leukemia (AML) is a hematopoietic progenitor/stem cell disorder in which neoplastic myeloblasts are stopped at an immature stage of differentiation and lost the normal ability of proliferation and apoptosis. MicroRNAs (miRNAs) are small noncoding, single-stranded RNA molecules that can mediate the expression of target genes. While miRNAs mean to contribute the developments of normal functions, abnormal expression of miRNAs and regulations on their corresponding targets have often been found in the developments of AML and described in recent years. In leukemia, miRNAs may function as regulatory molecules, acting as oncogenes or tumor suppressors. Overexpression of miRNAs can down-regulate tumor suppressors or other genes involved in cell differentiation, thereby contributing to AML formation. Similarly, miRNAs can down-regulate different proteins with oncogenic activity as tumor suppressors. We herein review the current data on miRNAs, specifically their targets and their biological function based on apoptosis in the development of AML.
引用
收藏
页码:284 / 294
页数:11
相关论文
共 50 条
  • [21] Role of Tim 3 in acute myeloid leukemia
    Fasler-Kan, E.
    Berger, S.
    Gibbs, B.
    Sumbayev, V.
    FEBS JOURNAL, 2017, 284 : 280 - 280
  • [22] A Role for Lipid Mediators in Acute Myeloid Leukemia
    Loew, Andreas
    Koehnke, Thomas
    Rehbeil, Emma
    Pietzner, Anne
    Weylandt, Karsten-H.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (10)
  • [23] Histamine revisited: Role in acute myeloid leukemia
    Bhandari, Prasan R.
    CLINICAL CANCER INVESTIGATION JOURNAL, 2013, 2 (04): : 287 - 293
  • [24] A critical role for Lyn in acute myeloid leukemia
    Dos Santos, Ceric
    Demur, Ceile
    Bardet, Valeie
    Prade-Houdellier, Nais
    Payrastre, Bernard
    Recher, Christian
    BLOOD, 2008, 111 (04) : 2269 - 2279
  • [25] The role of IDH mutations in acute myeloid leukemia
    Montalban-Bravo, Guillermo
    DiNardo, Courtney D.
    FUTURE ONCOLOGY, 2018, 14 (10) : 979 - 993
  • [26] The role of various interleukins in acute myeloid leukemia
    Kaser, Erin C.
    Zhao, Lei
    D'mello, Kyle P.
    Zhu, Ziwen
    Xiao, Huaping
    Wakefield, Mark R.
    Bai, Qian
    Fang, Yujiang
    MEDICAL ONCOLOGY, 2021, 38 (05)
  • [27] ROLE OF CHEMOTHERAPY IN TREATING ACUTE MYELOID LEUKEMIA
    DIAZMEDIAVILLA, J
    CARMONA, AMA
    REVISTA CLINICA ESPANOLA, 1989, 184 (04): : 165 - 167
  • [28] Role of angiogenesis inhibitors in acute myeloid leukemia
    Fiedler, W
    Staib, P
    Kuse, R
    Dührsen, U
    Flasshove, M
    Cavalli, F
    Hossfeld, DK
    Berdel, W
    CANCER JOURNAL, 2001, 7 : S129 - S133
  • [29] Role of postinduction immunotherapy in acute myeloid leukemia
    Klingemann, HG
    LEUKEMIA, 1996, 10 : S21 - S22
  • [30] The role of prognostic factors in acute myeloid leukemia
    Buchner, T
    Heinecke, A
    LEUKEMIA, 1996, 10 : S28 - S29